IQ-AI LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.55 GBX | -6.06% |
|
-3.12% | -67.02% |
| May. 10 | IQ-AI subsidiary gets rare paediatric disease designation FDA | AN |
| May. 10 | IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2.587 | 5.304 | 17.44 | 10.95 | 3.333 | 8.962 |
| Enterprise Value (EV) 1 | 2.622 | 4.496 | 17.05 | 10.28 | 3.081 | 8.823 |
| P/E ratio | -2.64 x | -7.93 x | -21.1 x | -20.7 x | -6.52 x | -13.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 15.7 x | 19.8 x | 68.3 x | 21 x | 6.22 x | 14.7 x |
| EV / Revenue | 15.9 x | 16.8 x | 66.8 x | 19.7 x | 5.75 x | 14.5 x |
| EV / EBITDA | -3.67 x | -9.42 x | -30 x | -28.8 x | -8.55 x | -30.3 x |
| EV / FCF | -6.14 x | -5.82 x | 115 x | -59.4 x | -18.4 x | -133 x |
| FCF Yield | -16.3% | -17.2% | 0.87% | -1.68% | -5.43% | -0.75% |
| Price to Book | 3.39 x | 3.33 x | 16.3 x | 9.2 x | 4.71 x | 94.6 x |
| Nbr of stocks (in thousands) | 120,346 | 134,275 | 170,108 | 182,508 | 182,621 | 190,672 |
| Reference price 2 | 0.0215 | 0.0395 | 0.1025 | 0.0600 | 0.0182 | 0.0470 |
| Announcement Date | 4/30/19 | 5/4/20 | 4/20/21 | 4/28/22 | 4/25/23 | 4/29/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.165 | 0.2679 | 0.2553 | 0.5211 | 0.5359 | 0.6094 |
| EBITDA 1 | -0.7149 | -0.4771 | -0.5692 | -0.3569 | -0.3603 | -0.2909 |
| EBIT 1 | -0.7484 | -0.5881 | -0.6857 | -0.4903 | -0.5009 | -0.4063 |
| Operating Margin | -453.67% | -219.55% | -268.58% | -94.1% | -93.47% | -66.68% |
| Earnings before Tax (EBT) 1 | -0.7641 | -0.6171 | -0.7175 | -0.5011 | -0.5116 | -0.6238 |
| Net income 1 | -0.7641 | -0.6387 | -0.7175 | -0.5011 | -0.5116 | -0.6238 |
| Net margin | -463.16% | -238.42% | -281.04% | -96.16% | -95.47% | -102.37% |
| EPS 2 | -0.008159 | -0.004981 | -0.004847 | -0.002900 | -0.002801 | -0.003395 |
| Free Cash Flow 1 | -0.4273 | -0.7729 | 0.1489 | -0.173 | -0.1673 | -0.0664 |
| FCF margin | -259.01% | -288.53% | 58.31% | -33.21% | -31.23% | -10.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/30/19 | 5/4/20 | 4/20/21 | 4/28/22 | 4/25/23 | 4/29/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.03 | - | - | - | - | - |
| Net Cash position 1 | - | 0.81 | 0.39 | 0.67 | 0.25 | 0.14 |
| Leverage (Debt/EBITDA) | -0.0477 x | - | - | - | - | - |
| Free Cash Flow 1 | -0.43 | -0.77 | 0.15 | -0.17 | -0.17 | -0.07 |
| ROE (net income / shareholders' equity) | -113% | -50.9% | -52.5% | -44.3% | -53.9% | -156% |
| ROA (Net income/ Total Assets) | -54.7% | -25.5% | -26% | -20.3% | -22% | -26.4% |
| Assets 1 | 1.397 | 2.508 | 2.764 | 2.466 | 2.33 | 2.366 |
| Book Value Per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0 | 0 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0 | 0 | 0 | 0 |
| Capex | - | 0 | - | 0.01 | 0 | - |
| Capex / Sales | - | 1.52% | - | 1.13% | 0.28% | - |
| Announcement Date | 4/30/19 | 5/4/20 | 4/20/21 | 4/28/22 | 4/25/23 | 4/29/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -64.89% | 4.58M | |
| -15.77% | 8.49B | |
| +58.90% | 4.08B | |
| -39.78% | 2.42B | |
| -10.33% | 2.42B | |
| -2.74% | 2.33B | |
| -2.53% | 2.01B | |
| -19.90% | 1.53B | |
| -38.30% | 1.26B | |
| +2.19% | 1.07B |
- Stock Market
- Equities
- IQAI Stock
- Financials IQ-AI Limited
